These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 28405961

  • 1. Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.
    Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A.
    Adv Ther; 2017 May; 34(5):1145-1156. PubMed ID: 28405961
    [Abstract] [Full Text] [Related]

  • 2. Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.
    Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guérin A.
    Adv Ther; 2017 Jul; 34(7):1673-1685. PubMed ID: 28578501
    [Abstract] [Full Text] [Related]

  • 3. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.
    Tan DS, Araújo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.
    J Thorac Oncol; 2016 Sep; 11(9):1550-7. PubMed ID: 27288979
    [Abstract] [Full Text] [Related]

  • 4. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E.
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 7. Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.
    Crinò L, Ahn MJ, De Marinis F, Groen HJ, Wakelee H, Hida T, Mok T, Spigel D, Felip E, Nishio M, Scagliotti G, Branle F, Emeremni C, Quadrigli M, Zhang J, Shaw AT.
    J Clin Oncol; 2016 Aug 20; 34(24):2866-73. PubMed ID: 27432917
    [Abstract] [Full Text] [Related]

  • 8. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.
    Lancet Oncol; 2016 Apr 20; 17(4):452-463. PubMed ID: 26973324
    [Abstract] [Full Text] [Related]

  • 9. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
    Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.
    Jpn J Clin Oncol; 2018 Apr 01; 48(4):367-375. PubMed ID: 29474558
    [Abstract] [Full Text] [Related]

  • 10. Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset.
    Hida T, Satouchi M, Nakagawa K, Seto T, Matsumoto S, Kiura K, Nokihara H, Murakami H, Tokushige K, Hatano B, Nishio M.
    Jpn J Clin Oncol; 2017 Jul 01; 47(7):618-624. PubMed ID: 28369553
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculli M, Xie J, Dalal A, Culver K.
    J Med Econ; 2018 Jun 01; 21(6):577-586. PubMed ID: 29458286
    [Abstract] [Full Text] [Related]

  • 12. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J.
    Lung Cancer; 2016 Aug 01; 98():9-14. PubMed ID: 27393500
    [Abstract] [Full Text] [Related]

  • 13. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.
    Gainor JF, Tan DS, De Pas T, Solomon BJ, Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet L, Yeap BY, Engelman JA, Shaw AT.
    Clin Cancer Res; 2015 Jun 15; 21(12):2745-52. PubMed ID: 25724526
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.
    Hurry M, Zhou ZY, Zhang J, Zhang C, Fan L, Rebeira M, Xie J.
    J Med Econ; 2016 Oct 15; 19(10):936-44. PubMed ID: 27149298
    [Abstract] [Full Text] [Related]

  • 15. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Cho BC, Kim DW, Bearz A, Laurie SA, McKeage M, Borra G, Park K, Kim SW, Ghosn M, Ardizzoni A, Maiello E, Greystoke A, Yu R, Osborne K, Gu W, Scott JW, Passos VQ, Lau YY, Wrona A.
    J Thorac Oncol; 2017 Sep 15; 12(9):1357-1367. PubMed ID: 28729021
    [Abstract] [Full Text] [Related]

  • 16. Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer.
    Won B, Mambetsariev I, Salgia R.
    BMC Cancer; 2016 Aug 02; 16():568. PubMed ID: 27480287
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Modalities of use of ceritinib (Zykadia™), a 2nd generation ALK inhibitor, in advanced stage non-small cell lung cancer].
    Giroux Leprieur E, Fallet V, Wislez M.
    Bull Cancer; 2015 Dec 02; 102(12):1053-7. PubMed ID: 26597476
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.